Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
d-MAPPS™ Ophthalmic Solution in Chronic Ocular Graft-Versus-Host Disease (oGVHD)
NCT06852768Phase 2Active, not recruiting
- Sponsor
- Regenerative Ocular Immunobiologics, LLC
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Therapeutic Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic ocular graft-versus-host disease (oGVHD) comparing d-MAPPS with Placebo (2 arms). Primary endpoints: University of North Carolina Dry Eye Management Scale at 4 months and Ocular Surface Disease Index at 4 months. Started Jan 2025; status: active, not recruiting.
02
Drugs
d-MAPPS Ophthalmic Solution
03
Conditions
chronic ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT06852768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852768.